Last month, BioCryst trimmed down its pipeline to two drugs in complement-mediated diseases: BCX9930 and BCX10013. Fast-forward 45 days and BCX9930 is headed to the garbage can, too.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,